Baxter International Inc. BAX recently showcased THERANOVA, a new class of medium cut-off (MCO) dialysers at the European Renal Association and European Dialysis and Transplant Association (ERA-EDTA) Congress. Baxter also presented eight abstracts that investigated the efficacy of the THERANOVA dialyser.
The abstracts demonstrated that THERANOVA is capable of filtering out mid and large-sized toxins that standard haemodialysis fails to remove from end-stage kidney disease patients. Notably, presence of higher toxins in these patients can affect biological functions and increase cardiovascular risk.
Baxter stated that in-vitro studies have shown that the THERANOVA dialyser is capable of clearing large uremic toxins (such as β-2 microglobulin), much similar to a high-volume hemodiafiltration (HDF) therapy.
Baxter also noted that the THERANOVA dialyser has been designed to work with most standard haemodialysis machines, as compared to the HDF therapy that needs special equipment and ultrapure fluids. THERANOVA’s compatibility with most standard machines significantly lowers treatment cost.
Baxter has received CE marking for THERANOVA in Europe, Australia and New Zealand, among other countries. The company announced that the dialyser will be available in select countries in 2016, with additional launches planned for 2017. The launch will definitely expand Baxter’s in-center haemodialysis portfolio, particularly in international markets.
Meanwhile, the renal division continues to report steady results. In the recently concluded first quarter of 2016, the division reported sales of $898 million, up 5% driven by low double-digit growth in the US Peritoneal Dialysis business. The company sold more than 500 AMIA PD cyclers during the quarter.
Acute business grew nearly 20% driven by increased adoption of extracorporeal therapies, including Continuous Renal Replacement Therapy (CRRT) for acute kidney injuries. Baxter’s Chronic Hemodialysis segment reported low single-digit growth, a positive reversal from the trend witnessed in the year-ago quarter.
Baxter expects the renal product category to exceed $17 billion by 2021, on 6% growth in patient population. Aging population, expanding access in emerging markets and growing adoption of home therapies are the key catalysts.
Zacks Rank & Other Stocks to Consider
Currently, Baxter sports a Zacks Rank #1 (Strong Buy).
Other favorably ranked stocks in the same space include SurModics SRDX, IRadimed Corporation IRMD and Masimo Corporation MASI. All the three stocks sport the same Zacks Rank as Baxter.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>